Chimerix
- Country
- đşđ¸United States
- Ownership
- -
- Employees
- 72
- Market Cap
- $88M
- Introduction
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded in April 2000 and is headquartered in Durham, NC.
Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
- First Posted Date
- 2010-11-16
- Last Posted Date
- 2021-07-21
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 52
- Registration Number
- NCT01241344
- Locations
- đşđ¸
St. Louis Children's Hosptial, Saint Louis, Missouri, United States
đşđ¸Harvard-Children's Hospital Boston, Boston, Massachusetts, United States
đşđ¸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 5
- Registration Number
- NCT01161641
- Locations
- đşđ¸
Sanford Children's ( Sanford Research / USD), Sioux Falls, South Dakota, United States
đşđ¸Children's Hospital Los Angeles ( Gastroenterology & Nutrition), Los Angeles, California, United States
đşđ¸Division of Pediatric Cardiology, University of Michigan Health System, Ann Arbor, Michigan, United States
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 210
- Registration Number
- NCT01143181
- Locations
- đşđ¸
Children's Hospital of LA, Los Angeles, California, United States
đşđ¸University of Chicago, Chicago, Illinois, United States
đşđ¸Cleveland Clinic, Cleveland, Ohio, United States
A Safety, Tolerability and Pharmacokinetic Study of a Single Dose of CMX157 in Healthy Volunteers
- First Posted Date
- 2010-03-04
- Last Posted Date
- 2011-07-04
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 36
- Registration Number
- NCT01080820
- Locations
- đşđ¸
Covance, Madison, Wisconsin, United States
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
- First Posted Date
- 2009-07-20
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 239
- Registration Number
- NCT00942305
- Locations
- đşđ¸
UCLA Medical Center, Los Angeles, California, United States
đşđ¸Winship Cancer Institute at Emory University, Atlanta, Georgia, United States
đşđ¸UT Southwestern Medical Center at Dallas, Dallas, Texas, United States
CMX001 in Post-transplant Patients With BK Virus Viruria
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 29
- Registration Number
- NCT00793598
- Locations
- đşđ¸
Tulane Center for Abdominal Transplant, New Orleans, Louisiana, United States
đşđ¸Mt. Sinai Medical Center, New York, New York, United States
đşđ¸UNC Kidney Center, Chapel Hill, North Carolina, United States
Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 24
- Registration Number
- NCT00780182
- Locations
- đşđ¸
AAI Pharma, Rtp, North Carolina, United States
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
- Conditions
- Interventions
- First Posted Date
- 2007-04-09
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Chimerix
- Target Recruit Count
- 158
- Registration Number
- NCT00457951
- Locations
- đ¨đŚ
University of Toronto, Toronto, Ontario, Canada
đşđ¸Louisiana State University Health Sciences Center in Shreveport, Shreveport, Louisiana, United States
đ§đŞUniversity Hospital Gasthuisberg, Leuven, Belgium